标题
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
作者
关键词
-
出版物
Nature Reviews Nephrology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-10
DOI
10.1038/s41581-022-00535-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
- (2021) Taha Sen et al. Cell Metabolism
- Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial
- (2021) Nan Ye et al. CIRCULATION
- Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria
- (2021) Meg Jardine et al. Clinical Journal of the American Society of Nephrology
- Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
- (2021) David Z. I. Cherney et al. DIABETOLOGIA
- Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
- (2021) Shruti S Joshi et al. HEART
- Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
- (2021) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
- (2021) Li Shen et al. JACC-Heart Failure
- Cardiovascular Disease in Chronic Kidney Disease
- (2021) Joachim Jankowski et al. CIRCULATION
- Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation
- (2021) Hiddo J. L. Heerspink et al. Clinical Journal of the American Society of Nephrology
- Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors
- (2021) Husam Ghanim et al. DIABETES OBESITY & METABOLISM
- Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
- (2021) João Pedro Ferreira et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
- (2021) João Pedro Ferreira et al. Journal of the American Heart Association
- Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
- (2021) Michael Szarek et al. ANNALS OF INTERNAL MEDICINE
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial
- (2021) Milton Packer et al. CIRCULATION
- Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
- (2021) Frederik Persson et al. DIABETES CARE
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
- (2021) Brendon L Neuen et al. EUROPEAN HEART JOURNAL
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
- (2021) Scott D. Solomon et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
- (2021) Glenn M. Chertow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
- (2021) Hiddo JL. Heerspink et al. KIDNEY INTERNATIONAL
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Major Renal Outcomes in Heart Failure
- (2021) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
- (2021) John J.V. McMurray et al. JACC-Heart Failure
- Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial
- (2021) Hiddo J.L. Heerspink et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients
- (2020) Fatima AlKindi et al. TRANSPLANTATION PROCEEDINGS
- Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study
- (2020) Christie Rampersad et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study
- (2020) Carina Iskander et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
- (2020) Kieran F Docherty et al. EUROPEAN HEART JOURNAL
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
- (2020) Meg J. Jardine et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF
- (2020) Alice M. Jackson et al. CIRCULATION
- Epidemiology of heart failure
- (2020) Amy Groenewegen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements ( SCREAM ) Project
- (2020) Junichi Ishigami et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- P1003STUDY DESIGN OF THE ROTATION FOR OPTIMAL TARGETING OF ALBUMINURIA AND TREATMENT EVALUATION (ROTATE-3): A ROTATION STUDY OF DIFFERENT ALBUMINURIA LOWERING DRUGS CLASSES TO STUDY INDIVIDUAL DRUG RESPONSE IN DIABETIC AND NON-DIABETIC CKD
- (2020) Michele Provenzano et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan
- (2020) Scott D. Solomon et al. JACC-Heart Failure
- Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program
- (2020) Brendon L. Neuen et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF
- (2020) Pardeep S. Jhund et al. CIRCULATION
- Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
- (2020) Adeera Levin et al. Clinical Journal of the American Society of Nephrology
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
- (2020) Matthew R Weir et al. Clinical Kidney Journal
- Effects of Canagliflozin in Patients with Baseline eGFR
- (2020) George Bakris et al. Clinical Journal of the American Society of Nephrology
- Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
- (2020) Rosalie A. Scholtes et al. DIABETES CARE
- Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
- (2020) Silvio E. Inzucchi et al. DIABETES CARE
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
- (2020) Milton Packer et al. EUROPEAN HEART JOURNAL
- Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
- (2020) Megumi Oshima et al. KIDNEY INTERNATIONAL
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
- (2020) Ashish Sarraju et al. AMERICAN HEART JOURNAL
- Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
- (2020) Dora Oikonomaki et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
- (2020) Bettina J. Kraus et al. KIDNEY INTERNATIONAL
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus
- (2019) Thea Anine Strøm Halden et al. DIABETES CARE
- Hypertension in CKD: Core Curriculum 2019
- (2019) Elaine Ku et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects
- (2019) Motoaki Sano et al. CIRCULATION
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
- (2019) Takashi Maruyama et al. Diabetes Technology & Therapeutics
- How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
- (2019) Burkert Pieske et al. EUROPEAN HEART JOURNAL
- Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
- (2019) Brendon L. Neuen et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease
- (2019) C. David Mazer et al. CIRCULATION
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Testosterone Increases the Expression and Phosphorylation of AMP kinase α in Men with Hypogonadism and Type 2 Diabetes
- (2019) Husam Ghanim et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis
- (2019) Jan Menne et al. PLOS MEDICINE
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
- (2018) Motoaki Sano Journal of Cardiology
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Acute renal outcomes with SGLT-2 inhibitors - real world data analysis
- (2018) Avivit Cahn et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation
- (2016) Jozine M. ter Maaten et al. EUROPEAN JOURNAL OF HEART FAILURE
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
- (2016) Yshai Yavin et al. Diabetes Therapy
- Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
- (2016) Yshai Yavin et al. Diabetes Therapy
- The kidney in heart failure: an update
- (2015) Kevin Damman et al. EUROPEAN HEART JOURNAL
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data
- (2015) Kunihiro Matsushita et al. Lancet Diabetes & Endocrinology
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
- (2013) Muhammad Abdul-Ghani et al. Endocrine Practice
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Notice
- (2012) Kidney International Supplements
- Systolic Heart Failure
- (2010) John J.V. McMurray NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
- (2009) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now